Printer Friendly

CLINICAL TRIAL COMMENCES USING INTERFERON SCIENCES' INTERFERON ALFA-N3 IN ASYMPTOMATIC HIV INFECTED PATIENTS AT WALTER REED

CLINICAL TRIAL COMMENCES USING INTERFERON SCIENCES' INTERFERON ALFA-N3
 IN ASYMPTOMATIC HIV INFECTED PATIENTS AT WALTER REED
 NEW BRUNSWICK, N.J., March 23 /PRNewswire/ -- Walter Reed Army Institute of Research and Interferon Sciences, Inc. (NASDAQ-NMS: IFSC), announced today the commencement of a Phase I clinical trial in asymptomatic HIV (Human Immunodeficiency Virus) infected patients utilizing Interferon Sciences' injectable formulation of interferon alfa-n3 (human leukocyte derived).
 The clinical trial is being conducted by Walter Reed Army Institute of Research and the National Naval Medical Center. The objective of this clinical investigation is to determine the safety and tolerance of subcutaneous injections of interferon alfa-n3 in asymptomatic HIV- positive individuals and to record their effects on the HIV virus in these patients. Several different dose levels of interferon alfa-n3 will be administered to 20 patients over a 12-week period.
 In vitro experimentation conducted at Walter Reed using Interferon Sciences' interferon alfa-n3 indicated that unexpectedly low concentrations were able to block the production of HIV virus. This trial is expected to help determine whether this laboratory finding may be relevant to the treatment of asymptomatic HIV infected patients.
 Major Donald Skillman of Walter Reed Army Institute of Research stated that this study is being conducted in view of prior published studies which reported that treatment with high doses of recombinant alpha interferon can result in a decline in HIV isolation in asymptomatic HIV infected patients.
 The results of in vitro experiments with interferon alfa-n3 may not be indicative of results in humans, Interferon Sciences cautioned. In addition, since tests have not previously been conducted for the treatment of HIV infected patients with injectable interferon alfa-n3 and additional tests would be necessary before the safety and effectiveness for this use could be established, it is not recommended or approved for such use, the company added.
 The study is being funded by Purdue Pharma L.P., whose affiliate, The Purdue Frederick Company, is marketing Interferon Sciences' ALFERON(R) N Injection for Purdue Pharma in the United States. ALFERON N Injection is the only natural-source, multi-subspecies alpha interferon for sale in the United States, and is approved for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
 Samuel H. Ronel, president of ISI, stated that the commencement of this clinical study further demonstrates Purdue's commitment to exploring new potential uses of ALFERON N Injection.
 Founded in 1980, Interferon Sciences, Inc. is a 53 percent owned subsidiary of National Patent Development Corporation (AMEX, PSE: NPD). The company is engaged in the manufacture and sale of ALFERON N Injection and the research and development of other alpha interferon based products for the potential treatment of viral diseases, cancers and diseases of the immune system.
 -0- 3/23/92
 /CONTACT: Paul Klein of Walter Reed, 301-295-6953; or Samuel H. Ronel, president, 908-249-3250, or Lawrence M. Gordon, Esq., vice president and general counsel, 212-230-9513, both of Interferon Sciences/
 (IFSC NPD) CO: Interferon Sciences Inc. ST: New Jersey, Maryland IN: MTC SU:


GK-SH -- NY007 -- 0419 03/23/92 09:13 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 23, 1992
Words:508
Previous Article:ZWEIG FUND DECLARES DISTRIBUTION OF 29 CENTS
Next Article:COMMUNICATIONS SATELLITE CONFERENCE AND EXHIBIT TO BE HELD IN WASHINGTON
Topics:


Related Articles
INTERFERON SCIENCES REPORTS 1991 OPERATING RESULTS
INTERFERON SCIENCES, INC. REPORTS FIRST QUARTER RESULTS
Interferon Sciences Reports 1996 Operating Results and Clinical Status Update
Interferon Sciences Announces Sale of 4,000,000 Shares of Common Stock.
Interferon Sciences Inc. Stockholders Approve One-For-Five Reverse Common Stock Split.
Interferon Sciences' Common Stock Delisted From Nasdaq.
Interferon Sciences Announces Results of FDA Prefiling Conference.
FDA ASSIGNS PRIORITY REVIEW STATUS TO PEG-INTRON/REBETOL.
Hemispherx Acquires Rights for Only FDA Approved Natural Alpha Interferon Drug Company; Completes a $5,500,000 Private Placement.
Pegasys-Copegus.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters